Antimicrobial Stewardship & Healthcare Epidemiology (Jan 2024)

Levofloxacin prophylaxis for pediatric leukemia patients: monitoring of outcomes for sustained benefit and consequences

  • Andrea L. Davis,
  • Alexandra M. Stevens,
  • Julienne Brackett,
  • Lucila Marquez,
  • Catherine E. Foster,
  • Adriana Sarmiento Clemente,
  • Hannah E. Sauer,
  • Grant T. Stimes,
  • Judith R. Campbell

DOI
https://doi.org/10.1017/ash.2024.81
Journal volume & issue
Vol. 4

Abstract

Read online

Levofloxacin prophylaxis reduces bloodstream infections in neutropenic patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. A retrospective, longitudinal cohort study compares incidence of bacteremia, multidrug-resistant organisms (MDRO), and Clostridioides difficile (CDI) between time periods of levofloxacin prophylaxis implementation. Benefits were sustained without increasing MDRO or CDI.